TSLP is the master switch for asthma treatment

An inflammatory cytokine protein TSLP that is released from epithelial cells in response to irritating stimuli may be the next target for a new class of anti-asthma therapies, Canadian researchers say.

In a proof-of-concept trial of a monoclonal antibody treatment against thymic stromal lymphopoietin (TSLP), researchers showed that blocking this “master switch” prevented allergen-induced bronchoconstriction.

In a study in the NEJM this month, researchers from xxx showed that five to 12 weeks of treatment with a